Ascendis Pharma A/S · ASND · FY2026 Q3 · Calendar Q4 2026

Ascendis Q3 growth broadens the story, while execution risks remain

The quarter strengthens the case that demand for Ascendis’s existing rare-disease products and expansion of the TransCon pipeline can support growth. Sustaining that trajectory depends on patient uptake, regulatory progress and execution as the company expands internationally.

Why did ASND rise 3.0% after beating EPS estimates in FY2026 Q3?

Research this report with FN2. Free to start; review your question before sending.

Reported Before market openNASDAQHealthcare $17.57B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $1.24 Consensus $0.89
EPS surprise +38.7% Reported versus consensus
Reported revenue $418.8M Consensus $409.4M
Revenue surprise +2.3% Reported versus consensus
Check the math in the surprise calculator >

Market reaction

prior-close to event-session close
Stock move +3.0% Event window
SPY move -0.4% Same window
Abnormal move +3.4% Stock minus SPY
Volume 2.0× Versus trailing sessions
Subsequent drift 0.0% Up to 20 sessions
ASNDSPY benchmark

Ask FN2 about ASND FY2026 Q3

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Transcript intelligence

What changed

Management reported Q3 revenue growth of 89% to EUR 366 million, led by Yorvipath, with growth also from Yuvivel and Skytrofa. Compared with the prior quarter’s account of early Yuvivel expansion and planned global rollout, the current analysis adds a positive CHMP opinion for Yuvivel and a planned Germany launch in Q1 2027; management maintained its guidance and long-term targets.

Guidance delta

Guidance was maintained. Management reaffirmed its target of more than EUR 5 billion in annual revenue by 2030; the supplied analysis does not report a change to guidance.

Key takeaways

  • Q3 revenue growth was driven by Yorvipath, with Yuvivel and Skytrofa also contributing.
  • Management identified existing-product growth, indication expansion and new TransCon-derived products as its three growth drivers.
  • The company reported full commercialization in 13 countries and plans to enter at least 15 additional markets in 2027.
  • The supplied analysis says operating expenses fell year over year and operating cash flow was strong; it does not provide further detail here.

Management priorities

  • Sustain patient demand for existing products and expand into additional markets.
  • Advance indication-expansion studies and the Phase III COAST combination trial.
  • Develop at least one new TransCon-based product each year and expand commercial presence to more than 50 countries.
  • Prepare for Yuvivel’s European rollout, including the planned Germany launch in Q1 2027.

Follow ASND with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
ASND EPS earnings history estimate and actual scatter chart 9 reported fiscal quarters and 4 future estimate-only quarters. Q4 '23 estimate $-2.15 Q4 '23 actual $-1.66, beat Q1 '24 estimate $-1.57 Q1 '24 actual $-2.48, miss Q2 '24 estimate $-1.54 Q2 '24 actual $-2.05, miss Q2 '25 estimate $-1.42 Q2 '25 actual $-0.93, beat Q3 '25 estimate $-0.41 Q3 '25 actual $-1.17, miss Q4 '25 estimate $-0.06 Q4 '25 actual $-0.64, miss Q1 '26 estimate $0.19 Q1 '26 actual $0.32, beat Q2 '26 estimate $1.71 Q2 '26 actual $3.29, beat Q3 '26 estimate $0.90 Q3 '26 actual $1.24, beat Q4 '26 estimate $1.59 Q1 '27 estimate $1.94 Q2 '27 estimate $2.38 Q3 '27 estimate $2.69
Show less

Analyst Consensus ?

ConsensusBuy26 ratings
Bullish2492.3%
Neutral27.7%
Bearish00.0%

Analyst 52W Price Targets

$252.73Current
$136Low
$274.39Average
$352High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Citigroup Buy BuyMaintainOct 26, 2026
Cantor Fitzgerald Overweight OverweightMaintainSep 25, 2026
Raymond James Outperform Strong BuyDowngradeSep 15, 2026
Oppenheimer Outperform OutperformMaintainSep 2, 2026
Wedbush Outperform OutperformMaintainSep 1, 2026
Show 21 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $252.73. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
JefferiesKelly Shi$300$262.68 +18.7%Nov 17, 2026
RBC CapitalAnalyst unavailable$352$274.24 +39.3%Nov 13, 2026
KeyBancAnalyst unavailable$330$267.07 +30.6%Nov 13, 2026
Canaccord GenuityAnalyst unavailable$268$243.37 +6.0%Oct 26, 2026
CitigroupEric Joseph$330$243.37 +30.6%Oct 26, 2026
See 59 more

Track every rating change on ASND the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.

Historical context

All ASND earnings

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
ALC Alcon Inc. FY2026 Q3 · Calendar Q4 2026 +2.2% -2.3% Alcon holds FY outlook as new launches meet IOL competition

Latest beats and misses

Who reports next

Get the ASND recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-11-12T15:09:40.111378+00:00
  2. FN2 earnings calendar · 2026-11-13T01:23:13.362233+00:00
  3. Polygon adjusted daily market bars · 2026-11-13T03:30:44.963207+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-13T03:30:44.960359+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-11-13. For educational purposes only; not investment advice.